Barbara Seitz-Polski Selected Research

Phospholipase A2 Receptors

12/2020	Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.
1/2019	Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation.
1/2019	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
1/2019	Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
1/2018	Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.
4/2017	[Membranous nephropathy: Pathophysiology and natural history].
1/2016	Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.
11/2015	Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.
12/2014	Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
6/2013	Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Seitz-Polski Research Topics

Disease

18	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2022 - 06/2013
8	COVID-19 01/2022 - 01/2020
8	Proteinuria 01/2021 - 12/2014
5	Neoplasms (Cancer) 01/2022 - 05/2014
5	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 06/2013
3	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2021 - 04/2017
2	Nervous System Diseases (Neurological Disorders) 01/2022 - 09/2016
2	Neuromyelitis Optica (Devic's Disease) 01/2022 - 12/2018
1	Multiple Myeloma 01/2022
1	Central Nervous System Vasculitis 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Immune System Diseases (Immune Disorders) 01/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Chilblains (Chilblain) 01/2021
1	Cross Infection (Nosocomial Infection) 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Myasthenia Gravis 01/2021
1	Neutropenia 01/2021
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2021
1	Cytokine Release Syndrome 01/2020
1	Infections 01/2020
1	Albuminuria 01/2020
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2017
1	Hidradenitis Suppurativa 01/2017
1	Inflammation (Inflammations) 09/2016
1	Multiple Sclerosis 09/2016
1	Demyelinating Diseases (Demyelinating Disease) 09/2016
1	Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) 09/2016
1	Kidney Diseases (Kidney Disease) 05/2014

Drug/Important Bio-Agent (IBA)

10	Phospholipase A2 ReceptorsIBA 12/2020 - 06/2013
9	Rituximab (Mabthera)FDA Link 01/2022 - 12/2018
8	AntibodiesIBA 01/2022 - 05/2014
8	AutoantibodiesIBA 12/2020 - 06/2013
5	AntigensIBA 01/2022 - 05/2014
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2013
5	ThrombospondinsIBA 12/2020 - 12/2014
5	EpitopesIBA 01/2020 - 01/2016
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2016
4	AutoantigensIBA 12/2020 - 01/2016
3	Biological ProductsIBA 01/2022 - 01/2021
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2017
3	VaccinesIBA 01/2022 - 01/2021
2	mRNA VaccinesIBA 11/2021 - 01/2021
2	Serum AlbuminIBA 01/2021 - 01/2018
2	InterferonsIBA 01/2020 - 01/2020
2	Immunoglobulin G (IgG)IBA 01/2020 - 12/2014
1	Complement System Proteins (Complement)IBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	Interferon-alpha (Interferon Alfa)IBA 01/2021
1	NivolumabIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	CreatineIBA 01/2021
1	fibrin fragment D (D-dimer)IBA 01/2021
1	Aldehyde Reductase (Aldose Reductase)IBA 12/2020
1	Phosphopyruvate Hydratase (Enolase)IBA 12/2020
1	Immunologic Factors (Immunomodulators)IBA 01/2020
1	Immunoglobulin A (IgA)IBA 01/2020
1	CytokinesIBA 01/2020
1	Interleukin-8 (Interleukin 8)IBA 01/2020
1	CreatinineIBA 01/2020
1	C-Reactive ProteinIBA 01/2017
1	Infliximab (Remicade)FDA Link 01/2017
1	Interleukin-17 (Interleukin 17)IBA 09/2016

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 06/2021 - 01/2021
2	Therapeutics 01/2021 - 01/2021
2	Kidney Transplantation 04/2017 - 12/2014
1	Nursing Care 01/2022
1	Patient Isolation 01/2022
1	Length of Stay 01/2021
1	Radiotherapy 01/2021
1	Precision Medicine 01/2020
1	Transplantation 12/2014